Investors
Mauna Kea Technologies
Stock Information
Mauna Kea Technologies
Stock Information
Stay up to date on all our investor news
0,0797€
Last updated
04/12/2025 - 08:24
+2,18%
€7.6m
Total sales in 2024
+40
Commercial opportunities following CellTolerance launch
+48%
PPU growth in 2024 vs.
2022
excluding exchange rates
Events and Presentations
Financial Results
Governance
Mauna Kea Technologies Shareholder Webinar (English subtitles available)
No results found.
MKT – Shareholder Webinar – Nov 18 2025
No results found.
Voting Rights Information – October 2025
No results found.
Corporate Presentation October 2025
No results found.
Mauna Kea Technologies Reports Third Quarter 2025 Revenue Up +16% at Constant Exchange Rates
No results found.
News
Mauna Kea Technologies and TaeWoong Medical USA Announce Exclusive Partnership to Accelerate Commercial Expansion in the U.S. in Pancreatic Cyst Management
Mauna Kea Technologies Receives NMPA Regulatory Approval in China for its Next-Generation Cellvizio® Platform
Mauna Kea Technologies Announces the Successful Completion of Its Financial Restructuring and €6M Capital Raise
No results found.
Shareholding Structure
A long term vision shared by major strategic shareholders: Johnson & Johnson (NYSE: JNJ) and Telix Pharmaceuticals (ASX : TLX)
Stock Information
STOCK MARKET DATA
Listed on Euronext Growth Paris
Initial listing : July 6, 2011
The number of outstanding shares is : 79,439,997
Industry : healthcare (4000)
Sector : Medical equipment and healthcare services (4530)
IDENTIFICATION CODES
ISIN : FR0010609263
Ticker : ALMKT
ANALYST COVERAGE
GILBERT DUPONT
Guillaume Cuvillier
EUROLAND CORPORATE
EUROLAND CORPORATE
Raphaël Génin
STATUTORY AUDITORS
• EY and Others, represented by Mr Franck SEBAG, 1-2 place des Saisons, 92400 Courbevoie- Paris La Défense, France